Key words: Pharmacogenomics, gene expression, inhaled corticosteroids, apoptosis, system biology Asthma is the most common chronic airway disease among children and young adults 1 characterized by airflow obstruction in the small airways of affected individuals. The prevalence of asthma and its mortality have almost doubled in the last 20 years, imposing an increasing financial burden on the medical care system. Despite the availability of many standard treatments, including b2-agonists, corticosteroids, and leukotriene antagonists, [2] [3] [4] to control asthmatic symptoms, almost half the patients with asthma do not see improvement in symptoms. Such variation in drug response is attributed to many factors, 5, 6 including genetics. [7] [8] [9] [10] Pharmacogenomic studies assess how genetic and genomic variation affects an individual's response to drug treatment. [11] [12] [13] [14] [15] Corticosteroids are the backbone of asthma therapies. They reduce inflammation through both gene activation and suppression. The molecular mechanisms of action of corticosteroids have been clearly described. 16 Failure of any of the steps along the route where corticosteroids pass from the cell membrane to their target genes may result in nonresponsiveness. For example, abnormalities in glucocorticoid receptor number, glucocorticoid receptor binding, or abnormalities in glucocorticoid-glucocorticoid receptor complex binding to DNA may result in poor response to corticosteroid therapy. [17] [18] [19] [20] Despite these insights, the molecular mechanisms underlying a given asthma patient's poor responsiveness to corticosteroid medications remain unclear.
Gene differential expression, single nucleotide polymorphism, and expression quantitative trait loci analyses have identified multiple genes associated with asthma drug responsiveness. 15, [21] [22] [23] However, these analyses typically focus on 1 gene at a time. Gene expression itself is regulated by several mechanisms, such as TFs, microRNAs, and DNA methylation. For complex diseases such as asthma, genes and their regulators are believed to work together; network approaches investigating asthmatic drug response should include consideration of both the genes and their upstream regulators.
It is well known that (1) transcription factors (TFs) play key roles in regulating gene expression; (2) TFs usually work together to coregulate gene expression; and (3) genes with similar functions tend to coexpress. Using this information, we have previously developed a message-passing model, called Passing Attributes between Networks for Data Assimilations (PANDA), 24 which assimilates information from multiple, complementary data types to reverse engineer a regulatory network. In this study, we apply PANDA to a set of immortalized B cells that were derived from inhaled corticosteroid (ICS)-treated patients with asthma who were part of a large clinical trial. We hypothesize that assessing the regulatory networks of poor and good clinical responders using PANDA could uncover the molecular mechanisms by which drug response to ICSs of each patient is determined.
METHODS

Asthma cohort
Childhood Asthma Management Program (CAMP) was a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of 3 inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting beta-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol. 25 The primary outcome measure was postbronchodilator FEV 1 percent of predicted (FEV 1 %), observed over a 4-to 6-year period. For this project, we selected 47 good responders and 48 poor responders from the 145 white CAMP subjects with available immortalized B cells (lymphoblastoid cell lines [LCLs]) gene expression. 15 The definitions of good responders and poor responders were based on the change in FEV 1 % between baseline and 2-month follow-up. We used the first tertile (Q1 5 1.10%) and the third tertile (Q3 5 9.78%) of FEV 1 change calculated on the basis of 145 subjects to partition the 145 subjects into 3 groups. The 48 subjects with FEV 1 change of less than Q1 were defined as poor responders; the 47 subjects with FEV 1 change of more than Q3 were defined as good responders.
LCL microarray experiment
As previously described, 15 immortalized B-cell lines (LCL) derived from 145 subjects with asthma from the CAMP clinical trial 25, 26 were cultured in RPMI 1640 medium and treated with dexamethasone (10 26 mol/L) or with sham (ethanol) for 6 hours. 22, 27, 28 After treatment, total RNAs were extracted and applied for microarray profiling. Gene expression levels of 22,184 gene probes for each sample were measured by using Illumina HumanRef-8 V2 chip (Illumina, San Diego, Calif).
Gene expression quality check
The gene expression data contained 201 arrays for dexamethasone-treated LCLs and 193 arrays for sham-treated LCLs. Approximately 10% of subjects had replicate arrays. We first did data quality check for the 2 treatment types of arrays separately. We then pooled the paired samples together and did log2 transformation and quantile normalization.
After data quality checking, 20,917 gene probes in 17,193 genes for 145 pairs of arrays were kept. The log2 difference of expression levels between dexamethasone-treated cell lines and sham-treated cell lines was used to measure the effect of drug treatment on the gene expression. Further details about data quality control can be found in this article's Online Repository at www.jacionline.org.
PANDA algorithm
PANDA is a message-passing model to construct directed networks between TFs and genes using multiple sources of genomic information to predict regulatory relationships. 24 The nodes in a PANDA network are TFs or genes. The directed edges extend from TFs to genes. Each edge has a weight value indicating the probability that a TF regulates a gene.
To seed the PANDA algorithm, we used a mapping between TF motifs and target genes. Descriptions of the creation of this mapping can be found in Glass et al. 29, 30 This mapping includes 255,051 pairs of (TF, gene) and 13,979 unique genes.
There are 13,191 genes shown in both our gene expression data and the mapping file. These 13,191 genes correspond to 240,939 pairs of (TF, gene) and correspond to 16,368 gene probes in our gene expression data.
Statistical analysis
We first evaluated the effect of glucocorticoid on gene expression by comparing the PANDA network for the 145 dexamethasone-treated cell lines with the network for their corresponding controls, 145 sham-treated cell lines. Specifically, we obtained a PANDA network for dexamethasone-treated cell lines and a PANDA network for sham-treated cell lines, respectively. In each network, edges connect TFs and their targeted genes. Because of the differences in gene expression between dexamethasone-treated cell lines and sham-treated cell lines, the edges and edge weights between the 2 networks are not the same. We call a TF as differentially connected (DC) if the TF connects to different sets of genes between the 2 PANDA networks. Differential connectivity between the 2 PANDA networks (dexamethasone vs sham) was revealed. We then compared the PANDA networks between the 47 good responders and 48 poor responders, focusing on the differential connectivity between the log2-difference in expression response -log2(dexamethasone) -log2(sham)-as the expression metric for a given individual.
Denote d i 5 w i,resp 2 w i,nonresp , where w i,resp is the edge weight for the ith pair of (TF, gene) for the good responders and w i,nonresp is the edge weight for the corresponding pair for the poor responders. We constructed the good-responder network of TFs and their targeted genes by adding edges to (TF, gene) pairs corresponding to the largest 10,000 d i . We then constructed the poor-responder network of TFs and their targeted genes by adding edges to (TF, gene) pairs corresponding to the smallest 10,000 d i . Denote S g as the set of TFs in the goodresponder network. Denote S p as the set of TFs in the poor-responder network. For the common TFs in both S g and S p , we calculated the number of edges that a TF has for good-responder network and poor-responder network, separately. Denote them as nEdge(g) and nEdge(p), respectively. We then calculated the difference of the edges nDiff 5 nEdge(g) 2 nEdge(p) and the ratio of the edges nRatio 5 nEdge(g)/nEdge(p) for each TF. The difference gives an absolute magnitude, whereas the ratio provides a gene-specific difference in the magnitude of differential regulation for a TF. For DC TFs (ie, TFs in both goodresponder network and poor-responder network), we tested whether they are differentially expressed (DE) between good responders and poor responders using a 2-sample t test.
To assess the statistical significance of the ratio of edges, we performed a permutation analysis. Specifically, we performed 1000 randomizations wherein we randomly divided LCLs into 2 groups and generated 2 corresponding networks. Denote Sg(r) and Sp(r) as the set of TFs in the top 10,000 pairs of (TF, gene) in these 2 ''random'' networks. As above, we identified the TFs in Sg(r) and Sp(r), calculated the number of edges for those TFs in Sg(r) and Sp(r), denoted as nEdge(gr) and nEdge(pr), respectively, and determined the ratio of edges, nEdge(gr)/nEdge(pr), for each TF. For each TF with a ratio greater than 1, we counted the total number of permutations where nEdge(gr)/nEdge(pr) > nEdge(g)/nEdge(p); for TFs with a ratio less than 1, we counted the total number of permutations where nEdge(gr)/ nEdge(pr) < nEdge(g)/nEdge(p). We then divided by the number of permutations in which that TF appears in the top (TF, gene) pairs to estimate how many times ''by chance'' one would expect to find a ratio more extreme that what was observed.
Pathway enrichment analysis
We obtained for each network the set of genes that were regulated by the TFs with differential connectivity (ie, TFs with large absolute difference of edge weights between the network of good responders and that of poor responders). We then compared the enriched pathways of the 2 sets of genes by using the functional annotation tool: the Database for Annotation, Visualization and Integrated Discovery. 31, 32 We expected that the 2 sets of enriched pathways would be different.
Gene silencing of TFs and dexamethasone treatment in LCLs
The TFs having most differential regulation may determine whether a patient is a good responder of ICS treatment or not. We chose to validate 2 key TFs (NFKB1 and JUN) with a different ratio of edges in good versus poor responders using a knockdown experiment. These 2 TFs were at polar ends of the ratio of the number of edges that a TF has in good-responder network to those in poor-responder network.
We hypothesized that knocking down the NFKB1 paralog (RELA) or JUN would result in modulation of the difference between poor responders and good responders. To validate this hypothesis, we cultured LCLs from 7 good responders and 7 poor responders in RPMI 1640 medium (Life Technologies) supplemented with 15% FBS. One siRNA with best knockdown efficiency in 3 individual siRNAs (ThermoFisher Scientific, Waltham, Mass) targeting JUN or RELA was chosen for the gene silencing experiment. Gene targeting siRNA and negative contol siRNA were transfected into LCL cell lines using 4D-Nucleofector X kit (Lonza, Allendale, NJ) with Nucleofector Program (EC-117). Optimal amount of siRNA (20-100 pmol siRNA/10 6 cells) was trasnsfected in each reaction. Twenty-four hours after transfection, cells were seeded into serum-free RPMI 1640 medium to starve for 24 hours followed by dexamethasone or vehicle control treatment (1 mM) for 2 hours. Total RNA was extracted from 7 good responder cell lines and 7 poor responder cell lines with or without dexamethasone treatment. By RT-PCR, we measured the expression levels of 4 downstream genes (CEBPD, MANBA, PPT2, and TCP1) for NFKB1 silencing, 5 downstream genes (ACOT8, ACSL3, MTA2, PDGFR8, and TMEM53) of JUN, and 1 housekeeping gene (GAPDH). RELA and JUN were measured for detecting the knockdown efficiency. We also measured the expression of NR3C1 gene that encodes the glucocorticoid receptor to determine whether there is endogenous expression difference of NR3C1 among good and poor responders. We generated histograms of the knockdown efficiencies of RELA and JUN across subjects. We also performed Western blotting to confirm TFs knockdown efficiency in LCL lines. The gene expression level of a gene in PCR analysis is inversely proportional to the CT level, where CT stands for cycles to reach to threshold. For a given gene, let delta CT 5 CT.gene 2 CT.GAPDH, where CT.gene is the CT level of the gene and CT.GAPDH is the CT level of GAPDH. For each downstream gene, we performed general linear model analysis to test whether delta CT levels for good responders are different from those for poor responders after dexamethasone treatment, adjusted for knockdown status (with TFs siRNA knockdown vs control siRNA knockdown).
Noting the key difference in apoptosis in the ontology analysis (Fig 1; see Table E2 in this article's Online Repository at www.jacionline.org), that is, proapoptosis enriched in network of good responders and antiapoptosis enriched in network of poor responders, we also measured cell viability in LCL lines after dexamethasone treatment. The cells were transfected by 2 different JUN siRNA (JUN siRNA-1 and JUN siRNA-2), RELA siRNA, and control siRNA. After starving for 24 hours, each siRNA-transfected cells were split into 8 wells and each 4 wells were treated with 0 mM (ethanol, solution vehicle) or 50 mM dexamethasone for 24 hours. The cell viability was detected by alamarBlue assay kit (ThermoFisher DAL1100). The results were normalized to relative ethanol-treated cells. Table I presents the population characteristics for the 145 subjects, the 48 poor responders, and the 47 good responders, separately. There are no significant differences between good responders and poor responders for age, sex, or baseline FEV 1 as a percent of predicted (FEV 1 %). The 2 groups have a significant difference between DFEV 1 (the change in FEV 1 % between baseline and 2-month follow-up) based on the definition of the 2 groups.
RESULTS
The networks of (TF, gene) for dexamethasone-treated LCLs and for sham-treated LCLs are shown in Fig 2, A and B , respectively. The complete set of TFs and their targeted genes are shown in Table E1 in this article's Online Repository at www.jacionline. org. The differential connectivity between the 2 networks indicates the effect of dexamethasone treatment on the transcription factor regulation of genes.
We next evaluate the differential connectivity between the network of good responders and that of poor responders. It would be difficult to visualize differential connectivity if we used all top 10,000 (TF, gene) pairs. Hence, we first illustrate the differential connectivity by using only the top 50 pairs of (TF, gene) that had the largest absolute differences of edge weights between the 2 networks (Fig 3) . In Fig 3, the red edges are from the network of good responders and the blue edges are from the network of poor responders. Fig 3 indicates that the 2 networks demonstrate extensive difference in connectivity. Interestingly, 7 of the 9 hot spots in Fig E1 in this article' s Online Repository at www.jacionline.org (networks of dexamethasone treatments) are also in Fig 3 (networks of responsiveness) , suggesting that key regulators of overall corticosteroid response are also important in regulating the clinical extremes of response. The The change in FEV 1 % between baseline and 2-month follow-up.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 target genes in good responders are listed in Table E3 , and the targets in poor responders are listed in Table E4 in this article's Online Repository at www.jacionline.org. The set S g (for good responders) contains 32 TFs and the set S p (for poor responders) contains 35 TFs. There are 31 TFs appearing in both S g and S p , including JUN and NFKB1 (Table II) . NFKB1 has the highest ratio (nEdge(g)/ nEdge(p) 5 20; P 5 .039 by permutation analysis) and JUN has the lowest ratio (nEdge(g)/nEdge(p) 5 .29; P 5 .019 by permutation analysis). Among the 31 unique TFs, 6 TFs have permutation P value of less than .05. For each of the 105 TFs in this study, we performed 2-sample t test to test whether a TF is DE between dexamethasone-treated LCLs and sham-treated LCLs. Fifty-one of the 105 TFs have a 2-sample t test P value of less than .05 (see Table E5 in this article's Online Repository at www.jacionline.org). Sixteen of the 31 common TFs are DE between dexamethasone-treated LCLs and sham-treated LCLs (Table II) . Of note, neither JUN nor NFKB1 was DE between dexamethasone-treated LCLs and sham-treated LCLs. We obtained the QQplot of -log10 (t test P value) between non-DC TFs and DC TFs (see Fig E3 in this article' s Online Repository at www.jacionline.org), which showed no significant difference between the 2 sets of TFs in terms of 2-sample t test P values. We also performed Fisher exact test to assess whether the differential expression of TFs (TFs with 2-sample t test P value of <.05 vs TFs with P value of > _.05) is associated with differential connection (TFs that are in both good-responder network and poor-responder network vs TFs that are not in both networks in 67 biological processes, including immune response and proapoptosis, and (2) the 225 genes that are only in S p (for poor responders) were enriched in 33 biological processes, including antiapoptosis. There are 2 overlapping biological processes (DNA metabolic process and DNA repair). Fig 1 is the heatmap of 2log10(P value) for enriched GO biological processes, where the P values are for testing whether a biological process is enriched or not based on the list of genes in the top 500 pairs of (TF, gene).
We next experimentally assessed the validity of regulatory networks built using PANDA. We hypothesized that these key TFs that differentiate the good-responder network from the poor-responder network contribute to differential effects of dexamethasone on cells. We assessed functional response along 2 lines: differential targeting of downstream gene expression between good and poor responders and differential cell viability (because apoptosis was a key phenotype differentiating response status in our pathway annotations). Among 31 TFs revealed by the PANDA method (Table II) , we choose NFKB1 and JUN for validation. Knockdown efficiencies of RELA and JUN across subjects are shown in Fig E2 in this article' s Online Repository at www.jacionline.org, which indicates that RELA knockdown efficiencies are good (median, 80%; range, 71%-85%) and JUN knockdown is less efficient (median, 32%; range, 8%-48%).
Western blotting image about the knockdown efficiency is shown in Fig E5 in this article' s Online Repository at www.jacionline.org.
The results of functional validation analysis of differential targeting showed that 1 of the 4 downstream genes (CEBPD) of NFKB1 has statistically lower delta CT level (ie, higher expression level) in good responders than in poor responders and that 1 of the 5 tested downstream genes (TMEM53) of JUN has a statistically higher delta CT level (ie, lower expression level) in good responders than in poor responders, after dexamethasone treatment and adjusting for siRNA knockdown (Table III and Fig 4) . The parallel boxplots of delta CT levels for all genes are shown in Figs E6 and E7 in this article's Online Repository at www.jacionline.org. For the cell viability assays, we compared the mean of the baseline-adjusted cell viability of good responder with that of poor responder for each of the 4 cell types (negative control, RELA siRNA, JUN siRNA-1, and JUN siRNA-2) with 50 mM dexamethasone treatment. Fig E4, A, in this article's Online Repository at www.jacionline.org shows the histogram of the cell viability adjusted for baseline for the 4 replicates. For negative control, there exists significant difference between good responders and poor responders in terms of cell viability. However, after knocking down RELA or JUN, the difference markedly decreased (Fig E4, B) . Six TFs (GATA3, NFATC2, SPI1, FEV, NFKB1, and JUN) have pval.Perm < .05 (boldface). stat.DiffExprs and pval.DiffExprs are test statistic and P value for testing whether a TF is DE between dexamethasone-treated cell lines and sham-treated cell lines by using 2-sample t test. Positive stat.DiffExprs indicates that mean expression levels of the TF in dexamethasone-treated cell lines is higher than that in sham-treated cell lines. Sixteen TFs have pval.DiffExprs < .05 (boldface). nDiff, nResp 2 nNonResp; nRatio, nResp/nNonResp; pval.Perm, P value for the significance of nRatio by permutation.
DISCUSSION
In this article, we showed that (1) PANDA can be applied to gene expression data generated from immortalized B-cell lines; (2) many TF hubs obtained from (TF, gene) networks characterizing the corticosteroid treatment effects on gene expression globally also appeared in (TF, gene) networks characterizing the ICS responsiveness specifically; (3) the network of good responders and that of poor responders have different connectivity and distinct ontologies; and (4) 1 downstream gene (CEBPD) of NFKB1 and 1 downstream gene (TMEM53) of JUN are DE between good responders and poor responders adjusting for siRNA knockdown, after dexamethasone treatment.
In the analysis of corticosteroid response alone, we identified 9 key ''hub'' TFs, each with at least 9 DC edges between treated and untreated (sham) cells. This suggests that these TFs may be transcriptional regulatory ''hot spots.'' A literature search indicated that there is biologic plausibility for a role in glucocorticoid signaling for at least 7 of the 9 TFs (Fig E1) . [33] [34] [35] [36] [37] [38] [39] [40] For example, ETS1 is a regulator of human glucocorticoid receptor 1A promoter. 35 The differential connectivity between the network of (TF, gene) we obtained for ICS good responders and that for ICS poor responders revealed multiple TFs that may help to explain why some children with asthma do not respond well to ICS treatment. From a mechanistic perspective, it is assuring that many of these TFs also play a role in the differential connectivity between the network of dexamethasone-treated cells and that of sham-treated cells. Indeed, 7 of the 9 key ''hub'' TFs in DC in dexamethasone versus sham were also present in the analysis of clinical responders (cf Fig E1) . These include GATA2, ETS1, YY1, and NFIC1, which all have well-documented roles in corticosteroid biology. 34, 35, [37] [38] [39] These findings support the notion that factors innately involved in the global response to corticosteroids may also modulate treatment response differences between subjects. Further studies of these TFs might help find a way to improve the efficiency of current ICS treatment.
A key feature of PANDA is the emphasis on differential connectivity as compared to differential expression of the TFs. Therefore, it is not surprising that the same sets of TFs regulated different sets of downstream genes between good responders and poor responders. Hence, the 2 networks had different ontologies. For good responders, these included regulation of the immune response and metabolic processes (Fig 1) . However, the most striking of the ontologic differences was that the network within good clinical responders supported ''proapoptosis'' pathways, whereas the network derived from poor responders indicated the presence of ''antiapoptosis'' pathway regulation. Corticosteroid-induced apoptosis is a known key mechanism related to resolution of asthmatic inflammation and helps to differentiate severe versus nonsevere asthma. [41] [42] [43] [44] Our findings add to this literature by eliciting the differential interactions between key TFs and their downstream targets as they modulate corticosteroid-induced apoptosis in good and poor responders.
Given this background, we chose to validate key TFs with a different ratio of edges in good versus poor responders using both downstream targeting approaches and a cellular apoptosis assay. In this functional validation analysis, we knocked out 2 key TFs (NFKB1 and JUN) from our network analysis using siRNA. NFKB1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1) encodes a 105-kD protein that can undergo cotranslational processing by the 26S proteasome to produce a 50-kD protein. Inappropriate activation of NFKB1 has been associated with a number of inflammatory diseases, whereas persistent inhibition of NFKB1 leads to inappropriate immune cell development or delayed cell growth. JUN (jun proto-oncogene) encodes a protein that is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression. Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. 45 In the functional validation analysis, we identified 1 downstream target (CEBPD) of NFKB1 and 1 downstream target (TMEM53) of JUN that are statistically DE following dexamethasone treatment in good versus poor responders, supporting differential connectivity of the TFs leading to different downstream gene targeting, as exemplified by differential expression, between good and poor ICS responders. We also observed that without knocking out the NFKB1 paralog (RELA) or JUN, the cell viability of good responders is statistically greater than that of poor responders. Importantly, such differences were largely abrogated after depletion of RELA or JUN by siRNA. Overall, this functional data suggest that RELA and JUN are playing important roles that determine differential cellular response to dexamethasone in these 2 groups of LCLs and, through generalization, to the differences in clinical response underlying the 2 groups. Thus, a malfunction of NFKB1 or JUN may explain the poor responsiveness of ICS treatment and that modulation of the connectivity related to these genes may be of therapeutic benefit. Further investigation is warranted.
Our study has a couple of limitations. One limitation of the present study is that the permutation P values in Table II are modest. We obtained Benjamini-Hochberg-corrected P values for the 31 TFs that we identified as targeted in the top/bottom edges to control for multiple testing (see Table E6 in this article's Online Repository at www.jacionline.org). Although no TFs are significant at a Benjamini-Hochberg-corrected P value of less than .05, the same 6 TFs we noted as nominally significant previously (including FEV, GATA3, JUN, NFATC2, NFKB1, and SPI1) were identified at a Benjamini-Hochberg-corrected P value of less than .15. In addition, when we investigated the siRNA-mediated changes in expression, we identified only 1 gene for each of the 2 TFs (NFKB1 and JUN). Although only 1 downstream gene for each TF was validated, there are plausible biologic and experimental reasons for this. From an experimental perspective, we note that the network was built upon more than 200 LCL cell lines and we choose only 7 cell lines for validation because of feasibility reasons. Therefore, it is likely that the sum total of target genes as inferred by the network analysis as derived from many samples may not be coregulated by the specific TF in exactly the same fashion as a single cell line under the same condition. Biologically, we also note that although there is usually a one-to-many relationship between a given TF and its downstream targets, there is often also a coregulation of gene expression by multiple TFs. Therefore, it is entirely possible that siRNA knockdown of a TF may not significantly alter the expression of such a gene. Both these points suggest that the regulation of gene expression remains complex and that functional validation of networks remains imperfect.
To assess whether the results of the network analysis are robust to the choice of the number of top edges used to define the networks, we calculated log2 ratio of the number of edges that a TF has in good-/poor-responder network for different numbers of top edges used (see Table E7 in this article's Online Repository at www.jacionline.org). We note that the ratios and especially the direction of enrichment are largely stable across different numbers of edges, especially as the number of selected edges increases (leading to more robust estimates). In addition, the higher thresholds (more edges) are likely more reliable in a sense because there is more overall information with greater numbers of edges (even if these edges are not the highest weight edges).
In permutation study, some TFs might be more easily found in the top and bottom edges compared with others. However, detailed examination shows that of the 31 TFs in Table II, 25 appear in both the positive and negative edges in all 1000 permutations and 29 appear in at least 800 permutations. The last column of Table E6 includes the number of permuted pairs of networks for which each TF appears in both the positive and negative set of edges.
Although we used immortalized B cells for this analysis, these cells were directly derived from clinical subjects participating in CAMP. Moreover, we recently described that the glucocorticoid receptor (the primary receptor for ICS), upon stimulation with dexamethasone, functions differently in these cells in good clinical ICS responders versus poor responders. 46 Using immortalized cell lines allows an analysis to be repeated many times on genetically identical cells, which is desirable and cost-effective for repeatable scientific experiments. One potential limitation of using immortalized cell lines is that immortalization might alter the biology of the cell. However, B lymphocytes are crucial inflammatory mediators in asthma. Moreover, Ding et al 47 recently reported that 70% of cisexpression quantitative trait loci in LCLs is shared with skin. Furthermore, our analysis showed the differential connectivity between good responders and poor responders. Combined, this evidence suggests that the results from an LCL analysis may also have large overlap with those from an analysis based on primary cells.
Conclusions
We have used PANDA to elucidate differences between good and poor clinical corticosteroid responders in asthma. Our functional results from 2 key TFs suggest that differential drug response networks built by the PANDA method are valid; further validation of other novel transcription regulators may yield additional biologic and translational insights into corticosteroid response. Our results indicate that biology between responders and poor responders does not necessarily emanate from differential expression, but may instead be from differential connectivity. 
